| Identification | Back Directory | [Name]
SGI 7079 | [CAS]
1239875-86-5 | [Synonyms]
CS-2333
SGI 7079
SGI-7079 /SGI7079
SGI-7079;SGI 7079;SGI7079
3-[2-[[3-Fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]benzeneacetonitrile
2-(3-(2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)acetonitrile
Benzeneacetonitrile, 3-[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]- | [Molecular Formula]
C26H26FN7 | [MDL Number]
MFCD28963942 | [MOL File]
1239875-86-5.mol | [Molecular Weight]
455.53 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 30 mg/ml; DMSO: 30 mg/ml; DMSO:PBS(pH 7.2) (1:3): 0.25 mg/ml | [form ]
A crystalline solid | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Description]
SGI-7079 is an inhibitor of the receptor tyrosine kinase Axl. It inhibits proliferation of inflammatory breast cancer cells (IC50s = 0.43 and 0.15 μM for SUM149 and KPL-4 cells, respectively), decreases invasion, and halts the cell cycle in the G1 phase. SGI-7079 synergistically increases the potency of erlotinib on EGFR inhibition. In a mouse xenograft model of non-small cell lung cancer, SGI-7079 dose-dependently inhibits tumor growth, an effect that is greater when used in combination with erlotinib. | [Uses]
3-[2-[[3-Fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]benzeneacetonitrile is an anticancer agent and a selective Axl inhibitor. | [IC 50]
Axl | [References]
[1] XIAOPING WANG. TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase.[J]. Cancer research, 2013, 73 21: 6516-6525. DOI: 10.1158/0008-5472.can-13-0967
[2] LAUREN AVERETT BYERS. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.[J]. Clinical Cancer Research, 2013: 279-290. DOI: 10.1158/1078-0432.ccr-12-1558 |
|
|